Blood flow is not the same as desire.
A compounded bremelanotide injection that enters sexual response through central melanocortin signaling rather than genital blood flow.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products. ## Updated copy: Women’s Hormone Therapy
About 10 minutes. No charge unless your clinician approves.
Desire starts upstream.
You can be physically capable of sex and still rarely feel the urge to begin it. That distinction matters because a treatment aimed at blood flow is answering a different question from the one you are actually asking.
PT-141 works further upstream.
PT-141, also called bremelanotide, activates melanocortin receptors in the central nervous system rather than directly increasing genital blood flow. Its target is central melanocortin signaling, which gives the molecule a distinct mechanism within sexual medicine.
There is real human evidence for the molecule, with an important boundary around it. Randomized, double-blind, placebo-controlled trials of the FDA-approved Vyleesi product found statistically significant improvement in measured desire and related distress in its approved study population.1 Those results give your clinician a defined evidence base to interpret while keeping the compounded prescription and your individual response separate from the studied product.
PT-141 belongs in a different lane from Viagra or Cialis. It is considered when the clinical question is desire and central signaling, with dosing guidance and licensed-pharmacy sourcing inside supervised care.
- Vyleesi (bremelanotide) Prescribing Information, current DailyMed record.DailyMed
For when desire itself is what changed.
The Initiation Shift
Sex can still matter to you while the spontaneous urge to begin it shows up less often. You want that change evaluated as its own clinical question.
The Slow Fade
Desire changed gradually enough that there was no dramatic before and after. You simply realized one day that wanting sex had become less automatic than it used to be.
The Unfinished Answer
You have already spent time addressing your sexual health and something still feels unresolved. You want the remaining question evaluated instead of assumed.
The preparation offered here is compounded, is not Vyleesi, and is not an FDA-approved drug product. FDA has not reviewed the compounded medication for safety, effectiveness or quality. Your clinician determines candidacy from your full Assessment.
This might not be the right fit if:
- You have uncontrolled high blood pressure or known cardiovascular disease.
- You are pregnant, think you may be pregnant, or are breastfeeding.
- You take oral naltrexone for alcohol or opioid dependence.
- You have a known hypersensitivity to any component of the preparation.
- You are under 18.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
PT-141, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- An independent licensed clinician reviews your Assessment and gives you a real answer either way.
- If approved, your clinician sets your dose and timing instead of leaving you to work them out alone.
- Your prescription is compounded by a licensed US pharmacy, with follow-up built into your care.
- Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products. ## Updated copy: Women’s Hormone Therapy
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Sexual Vitality.
Oxytocin
Closeness is not a performance metric.
A clinician-guided compounded oxytocin prescription for people exploring the social and emotional layer of intimacy.
Do not use if you have
- Uncontrolled hypertension, in which Vyleesi is contraindicated
- Known cardiovascular disease
Serious risks
- Vyleesi can temporarily raise blood pressure and lower heart rate
- Focal skin darkening can occur and may not fully resolve
- Bremelanotide can slow gastric emptying and affect absorption of oral medications
- It can also significantly reduce exposure to oral naltrexone, so naltrexone use needs to be disclosed before prescribing
Commonly reported
- Nausea, affecting roughly four in ten treated patients in phase 3 trials
- Flushing
- Injection-site reactions
- Headache
- Vomiting
Most safety data come from the FDA-approved Vyleesi product.
- Vyleesi (bremelanotide) Prescribing Information, current DailyMed record.DailyMed
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
No. Sildenafil and tadalafil primarily affect pathways involved in genital blood flow. Bremelanotide acts through melanocortin receptors in the central nervous system. They address different physiology, which is why the problem you are trying to solve matters as much as the medication being considered.
Bremelanotide is the active ingredient in Vyleesi, an FDA-approved prescription drug for acquired, generalized HSDD in certain premenopausal women. The preparation offered here is compounded and is not Vyleesi, and Vyleesi is not indicated for men, postmenopausal women or enhancement of sexual performance. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
The FDA-approved Vyleesi product improved measured sexual desire and related distress in randomized, placebo-controlled trials of its approved population.1 Those studies evaluated Vyleesi, not the compounded preparation offered here, and they do not establish the same result for other populations or compounded formulations. Individual response varies.
Desire is not one uniform symptom and PT-141 is not a promise with a clock attached to it. Your provider sets expectations from your health, the concern being treated, and what actually happens after treatment begins.
Bremelanotide has enough real pharmacology and enough real medical risk that self-directed access is the least interesting part of the product. Here, a licensed clinician reviews whether it belongs in your care and a licensed US pharmacy compounds it to your prescription. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. The meaningful difference is a medical system that knows exactly which evidence belongs to Vyleesi, which questions remain open for compounded treatment, and where you fit between the two.
- Vyleesi (bremelanotide) Prescribing Information, current DailyMed record.DailyMed
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.